Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Dec 07 2020

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 3 pages · English

Release

Cadila Healthcare Limited has informed the Exchange regarding a press release dated December 07, 2020, titled "Zydus announcesPhase I trials of ZYIL1, a novel oral small molecule NLRP3 inflammasome inhibitor".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases